Trial record 1 of 1 for:    NCT01829568
Previous Study | Return to List | Next Study

Rituximab, Lenalidomide, and Ibrutinib in Treating Patients With Previously Untreated Stage II-IV Follicular Lymphoma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01829568
Recruitment Status : Active, not recruiting
First Posted : April 11, 2013
Last Update Posted : March 5, 2018
Celgene Corporation
Information provided by (Responsible Party):
National Cancer Institute (NCI)

No Study Results Posted on for this Study
  Recruitment Status : Active, not recruiting
  Primary Completion Date : September 1, 2015
  Study Completion Date : No date given